Background: Brimonidine Tartrate (BRT) is used in the treatment of glaucoma. Brimonidine
tartrate nanoemulsion was fabricated in this research work to enhance the permeability through barriers
and faster onset of action and therapeutic effect.
Objective: To fabricate an ocular compatible nanoemulsion of brimonidine tartrate by using surfactant
Methods: The experimental work involved compatibility studies by using FTIR, DSC and crystallinity
study by XRD. The prepared nanoemulsion was studied by photon correlation spectroscopy by Malvern
S90 for the particle size analysis and characterized for Z average value (d.nm.) and PDI. Further studies
were conducted by laser light scattering technique by delsanano common and TEM.
Results: The study demonstrated that the formulations BN2, BN3, BN10 demonstrated the z average
value of 19.48, 22.14,26.50 d.nm. With 0.337, 0.270, 0.289 PDI respectively, the formulae BN2, BN3,
BN10 demonstrated the distribution average diameter (nm) of 376.8 + 258.4, 542.8 + 494.4, 398.8 +
263.9 with the diameter of 267.5, 298.5, 272.7, respectively. The zeta potential of BN10 was -21.26
mV and other parameters such as TEM and drug release studies were also reported.
Conclusion: The nanoemulsion of brimonidine tartrate was prepared successfully by using castor oil,
Lipoid S75 (Fat free soybean phospholipids with 70% phosphatidylcholine), Lipoid E80 (Egg phospholipids
with 80% phosphatidylcholine) and PF- 68. The optimised formula demonstrated the lower
droplet size, satisfactory zeta potential, and high drug loading and reproducible drug release profile.
Brimonididne taratarate is reported in various recent patents for various applications and is the potential
candidate for future therapy. Nanoemulsion is widely explored as potential alternatives for conventional
ophthalmic formulation based approaches. It enhances the ocular bioavailability by reducing the drug
protein binding, increasing the corneal resident time, enhancing the drug permeability and providing a
sustained drug release.It reported a significant increase in therapeutic efficacy for various chronic ocular
disease states of both the anterior and posterior ocular segments.